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ABSTRACT
Objective Fibroblast growth factors (Fgfs) are key
orchestrators of development, and a role of Fgfs in tissue
repair is emerging. Here we studied the consequences of
inducible loss of Fgf receptor (Fgfr) 4, the major Fgf
receptor (Fgfr) on hepatocytes, alone or in combination
with Fgfr1 and Fgfr2, for liver regeneration after PH.
Design We used siRNA delivered via nanoparticles
combined with liver-speciﬁc gene knockout to study Fgfr
function in liver regeneration. Liver or blood samples
were analysed using histology, immunohistochemistry,
real-time RT-PCR, western blotting and ELISA.
Results siRNA-mediated knockdown of Fgfr4 severely
affected liver regeneration due to impairment of
hepatocyte proliferation combined with liver necrosis.
Mechanistically, the proliferation defect resulted from
inhibition of an Fgf15-Fgfr4-Stat3 signalling pathway,
which is required for injury-induced expression of the
Foxm1 transcription factor and subsequent cell cycle
progression, while elevated levels of intrahepatic toxic
bile acids were identiﬁed as the likely cause of the
necrotic damage. Failure of liver mass restoration in
Fgfr4 knockdown mice was prevented at least in part by
compensatory hypertrophy of hepatocytes. Most
importantly, our data revealed partially redundant
functions of Fgf receptors in the liver, since knockdown
of Fgfr4 in mice lacking Fgfr1 and Fgfr2 in hepatocytes
caused liver failure after PH due to severe liver necrosis
and a defect in regeneration.
Conclusions These results demonstrate that Fgfr
signalling in hepatocytes is essential for liver
regeneration and suggest activation of Fgfr signalling as
a promising approach for the improvement of the liver’s
regenerative capacity.
INTRODUCTION
Fibroblast growth factors (Fgfs) comprise a family of
22 proteins in mammals, which control proliferation,
differentiation and survival of various cell types.
They exert their functions by activation of four trans-
membrane tyrosine kinase receptors, designated
Fgfr1–Fgfr4.1 2 Fgf expression is strongly upregu-
lated after injury to various tissues and organs as ini-
tially demonstrated for the skin.3 This is functionally
important since inhibition of Fgfr signalling in mice
caused impaired wound healing4 and also affected
the repair process of other organs.2 5 Therefore, Fgfs
are promising molecules for the treatment of
impaired tissue repair.
The liver is the only organ in adult mammals
that can fully regenerate even after severe injury.6 7
This remarkable regenerative capacity involves the
action of different growth factors, and ligands of
the epidermal growth factor receptor as well as
hepatocyte growth factor (Hgf) are considered as
the major mitogens for hepatocytes in the regener-
ating liver.7 8 Our previous studies also revealed a
Signiﬁcance of this study
What is already known on this subject?
▸ Fibroblast growth factor receptor (Fgfr)1 and
Fgfr2 on hepatocytes control compound
detoxiﬁcation in the regenerating liver.
▸ Global loss of Fgfr4 in mice does not cause an
obvious defect in liver regeneration after partial
hepatectomy.
▸ Loss of Fgf15, the major Fgfr4 ligand, strongly
impairs hepatocyte proliferation and causes
liver damage after partial hepatectomy.
What are the new ﬁndings?
▸ Inducible loss of Fgfr4 in the liver through
siRNA-mediated knockdown severely impairs
liver regeneration.
▸ Fgf15 levels increase in the serum after partial
hepatectomy and most likely activate Fgfr4 on
hepatocytes.
▸ Mechanistic studies reveal that an
Fgf15-Fgfr4-Stat3-FoxM1 axis controls
hepatocyte proliferation in the regenerating
liver.
▸ Combined loss of Fgfr1, Fgfr2 and Fgfr4 in
hepatocytes causes liver failure after partial
hepatectomy, demonstrating that Fgfr signalling
is essential for liver regeneration.
How might it impact on clinical practice in
the foreseeable future?
▸ Activation of Fgfr4 signalling through treatment
with the ligand Fgf15 or low-molecular-weight
compounds is a promising approach for the
improvement of liver regeneration, in particular
in patients with severe liver damage.
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role of Fgfs in this process since hepatocyte proliferation after
two-third (partial) hepatectomy (PH) was impaired in mice
expressing a dominant-negative Fgfr2 mutant in hepatocytes.9
Since this mutant inhibits signalling via different Fgfr to a differ-
ent extent, the role of individual receptors in the regenerative
response and their mechanisms of action remained, however,
unclear. Therefore, we studied the liver regeneration process in
mice lacking Fgfr1 and Fgfr2 in hepatocytes and identiﬁed an
important function of these receptors in compound detoxiﬁca-
tion, while the peak in hepatocyte proliferation was only mildly
affected.10 By contrast, no obvious regeneration defect after PH
was observed in mice with a global Fgfr4 knockout,11 although
Fgfr4 is the most abundant Fgfr on hepatocytes with an import-
ant function in liver tumorigenesis.12 13 Since mice with a
global knockout of a gene frequently activate compensatory
pathways during prenatal and/or postnatal development, we
studied the consequences of an inducible loss of this receptor in
adult mice for liver regeneration. We used siRNA formulated
into lipid nanoparticles, which allows an efﬁcient knockdown in
the liver after a single injection.14 The nanoparticles speciﬁcally
target hepatocytes due to an apolipoprotein E-dependent mech-
anism of delivery.15–17 Recently, we demonstrated the usefulness
of an siRNA approach to determine the role of β1-integrin in
liver regeneration.18 Importantly, the knockdown was only efﬁ-
cient in hepatocytes, but not in non-parenchymal liver cells.18
Using this approach, we determined the consequences of Fgfr4
knockdown for liver regeneration in the presence or absence of
Fgfr1 and Fgfr2 in hepatocytes. We demonstrate an important
role of Fgfr4 in liver regeneration and an essential role of Fgfr
signalling in general for this process.
MATERIALS AND METHODS
Animals
Wild-type mice, mice lacking Fgfr1 and Fgfr2 in hepatocytes10
and mice expressing Cre recombinase in hepatocytes (Alb-Cre
mice) were used in this study. They were maintained in a
pathogen-free facility under optimal hygiene conditions. Mouse
maintenance and all procedures with animals had been approved
by the local veterinary authorities of Zurich, Switzerland.
siRNA-mediated knockdown
siRNAs were formulated in lipid nanoparticles (ionisable
lipoids), which speciﬁcally target hepatocytes due to an apolipo-
protein E-dependent mechanism of delivery.15 16 17 Male mice
received formulated siRNA directed against luciferase (Luc) or
Fgfr4 (0.5 mg/kg) via tail vein injection in a volume of 5 mL/kg
body weight at days 1 and 5. PH was performed at day 10. The
following siRNAs were used:
Fgfr4 Sense 50-ccuGAuGcAucGAcAuuuAdTsdT-30
Antisense 50-uAAAUGUCGAUGcAUcAGGdTsdT-30
Fgfr4-2 Sense 50-GGcuGAAAcAcGucGucAudTsdT-30
Antisense 50-AUGACGACGUGUUUcAGCCdTsdT-30
Luciferase Sense 50-cuuAcGcuGAGuAcuucGAdTsdT-30
Antisense 50-UCGAAGuACUcAGCGuAAGdTsdT-30
20-OMe modiﬁed nucleotides are in lower case, and phos-
phorothioate linkages are indicated by ‘s’.
Partial hepatectomy
Eight-week to 10-week-old male mice, which had received
food and water ad libitum before surgery, were anaesthetised
by inhalation of isoﬂurane, and PH was performed in the
morning between 08:00 and 12:00.10 After PH, mice were
injected with buprenorphine for analgesia (Temgesic; Essex
Chemie AG, Luzern, Switzerland; 0.1 mg/kg of body weight).
They were euthanised by CO2 inhalation, and the remaining
liver was removed at different time points after PH. The liver
tissue that was removed during PH was considered 0 h time
point.
Histology and histomorphometry
Liver samples were ﬁxed in 4% paraformaldehyde in phosphate
buffered saline (PBS) or in 95% ethanol/1% acetic acid and
embedded in parafﬁn. Sections (3.5 mm) were stained with
H&E and photographed. The necrotic area was determined
morphometrically. For cell size measurement, acidic ethanol-
ﬁxed sections were permeabilised with Triton X-100 and the
actin cytoskeleton was stained with rhodamine-coupled phal-
loidin (Life Technologies, Carlsbad, California, USA). Nuclei
were counterstained with 40,6-diamidino-2-phenylindole.
Sections were mounted with Mowiol.
Identiﬁcation of proliferating cells in vivo
Proliferating cells were identiﬁed by 5-bromo-20-deoxyuridine
(BrdU) labelling 2 h before sacriﬁce. Liver sections were stained
with a BrdU antibody, and labelled cells were counted in four
independent microscopic ﬁelds (200× magniﬁcation) per
animal.10
Isolation of parenchymal and non-parenchymal cells from
mouse liver
Liver was perfused and digested, and hepatocytes and non-
parenchymal cells were separated as described.19
Terminal dUTP nick-end labelling
The In Situ Cell Death Detection Kit (Roche, Basel, Switzerland)
was used for the detection of apoptotic cells.
Serum analysis
After sacriﬁce, blood was taken by heart punctuation. After
coagulation, serum was harvested, snap-frozen and analysed
using FUJI DRI-CHEM 4000i and the corresponding reagents
(Fuji, Tokyo, Japan).
Immunohistochemistry
Parafﬁn sections were incubated for 30 min in 12% bovine
serum albumin in PBS/0.025% NP-40 to block unspeciﬁc
binding sites. The primary antibody (anti-Ly6G; BD
Pharmingen, Allschwil, Switzerland) was incubated overnight at
4°C. Sections were stained using the ABC Vectastain Peroxidase
Kit (Vector Laboratories, Burlingame, California, USA) accord-
ing to the manufacturer’s protocol, counterstained with haema-
toxylin, rehydrated and mounted.
RNA isolation and quantitative RT-PCR analysis
Isolation of total cellular RNA, cDNA synthesis and quantitative
RT-PCR (qRT-PCR) were carried out as described previously10
using the following primers:
Gapdh Forward: 50-TCG TGG ATC TGA CGT GCC GCC TG-30
Reverse: 50-CAC CAC CCT GTT GCT GTA GCC GTA T-30
Fgfr4 Forward: 50-TTG GCC CTG TTG AGC ATC TTT-30
Reverse: 30-GCC CTC TTT GTA CCA GTG ACG-30
Fgfr1 Forward: 50-CAA CCG TGT GAC CAA AGT GG-30
Reverse: 50-TCC GAC AGG TCC TTC TCC G-30
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Fgfr2 Forward: 50-ATC CCC CTG CGG AGA CA-30
Reverse: 50-GAG GAC AGA CGC GTT GTT ATC C-30
Fgfr3 Forward: 50-GTG GCT GGA GCT ACT TCC GA-30
Reverse: 50-ATC CTT AGC CCA GAC CGT GG-30
Foxm1 Forward: 50-TGA CAT TGG ACC AAG TGT TTA AGC-30
Reverse: 50-TCG TTT CTG CTG TGA TTACCAA GT-30
Cyclin D1 Forward: 50-GCG TAC CCT GAC ACC AAT CTC-30
Reverse: 50-ACT TGA AGT AAG ATA CGG AGG GC-30
Cyclin E1 Forward: 50-TCC ACG CAT GCT GAA TTA TC-30
Reverse: 50-TTG CAA GAC CCA GAT GAA GA-30
Cyclin A2 Forward: 50-CTT GGC TGC ACC AAC AGT AA-30
Reverse: 50-CAA ACT CAG TTC TCC CAA AAA CA-30
Cyclin B1 Forward: 50-GCG TGT GCC TGT GAC AGT TA-30
Reverse: 50-CCT AGC GTT TTT GCT TCC CTT-30
Cyp7a1 Forward: 50-GGG ATT GCT GTG GTA GTG AGC-30
Reverse: 50-CTG TTG CCC AAC TAA GGT ATG G-30
Fxr Forward: 50-GCTTGATGTGCTACAAAAGCTG-30
Reverse: 50-CGTGGTGATGGTTGAATGTCC-50
Tbp Forward: 50-AGA ACA ATC CAG ACT AGC AGC A-30
Reverse: 50-GCC CTC TTT GTA CCA GTG ACG-30
Cell culture
Mouse immortalised hepatocytes (AML12 cells), Hepa1-6 hepa-
toma cells and C2C12 myoblasts were cultured in DMEM/10%
FCS/penicillin/streptomycin.
Preparation of protein lysates and western blot analysis
Frozen tissue was homogenised in T-PER tissue protein extraction
reagent (Pierce, Rockford, Illinois, USA) containing Complete
Protease Inhibitor Cocktail and PhosSTOP Phosphatase Inhibitor
Cocktail (Roche). Lysates were cleared by sonication and
centrifugation.
Cultured cells were lysed in 1× Laemmli buffer at 95°C.
Proteins were analysed by western blotting using antibodies
against Fgfr4 (R&D Systems, Minneapolis, Minnesota, USA),
Gapdh (HyTest, Turku, Finland), Foxm1 and Cyp7a1 (Santa Cruz,
Santa Cruz, California, USA), phospho-STAT3 (Tyr-705) and
total-STAT3 (both from Cell Signaling, Beverly, Massachusetts,
USA).
Cell cycle analysis of cultured cells
Incorporation of 5-ethynyl-20-deoxyuridine (EdU) into DNA
was monitored by ﬂow cytometry using the Click-iT EdU Flow
Cytometry Assay kit (Invitrogen, Basel, Switzerland). The same
staining provided information on the cell cycle state of the cells.
Hepa1-6 cells were cultured in 6-well plates and transfected
with Luc or Fgfr4 siRNA (10 nM siRNA) using lipofectamine
(Sigma, Buchs, Switzerland). After 48 h incubation, EdU was
added to a ﬁnal concentration of 10 μM. Four hours later, cells
were removed by 5 min accutase treatment (1:10,
Lucerna-Chem, Luzern, Switzerland). Cells were analysed using
a BD LSRII Fortessa (BD, Allschwil, Switzerland) and FlowJo
V.8.7 software (Treestar, Ashland, Oregon, USA).
Determination of Fgf15 serum levels
Serum levels of Fgf15 were determined by ELISA
(Antibodies-online.com, Aachen, Germany) according to the
manufacturer`s instructions.
Cytokine multiplex ELISA
Cytokine concentrations were measured in 50 μg liver lysate
using the magnetic bead multiplex suspension array system
(Bio-Plex ProT Mouse Cytokine 23-plex Assay; BioRad;
Hercules, California, USA). Data were analysed using the
MagPix instrument and Bioplex Software (BioRad).
Bile acid quantiﬁcation
Bile acids were quantiﬁed by liquid chromatography-tandem
mass spectrometry (LC-MS/MS).20 Instead of serum, liver homo-
genates corresponding to 1.25 mg wet weight were analysed.
Statistical analysis
Statistical analysis was performed using the Prism6 software
(GraphPad Software, San Diego, California, USA). Quantitative
data are expressed as mean±SEM. Signiﬁcance was calculated
using Mann–Whitney U test; *p≤0.05, **p≤0.01, ***p≤0.001.
RESULTS
Impaired liver regeneration after siRNA-mediated
knockdown of Fgfr4
We used lipid-based nanoparticles to deliver Fgfr4 siRNA to
hepatocytes. Forty-four Fgfr4 siRNAs were tested for their in
vitro efﬁcacy using C2C12 mouse myoblasts, which express
high levels of Fgfr4. The most potent siRNAs—Fgfr4 and
Fgfr4-2 (see online supplementary ﬁgure S1A)—were packaged
into nanoparticles. siRNA against Luc was used as control.
Nanoparticles were injected into the tail vein at day 1 and day
5, and mice were subjected to PH 5 days later (ﬁgure 1A). The
initial analysis of non-injured liver and liver 48 h after PH was
performed with wild-type and Alb-Cre mice, and the results
were identical (data not shown). Since it was the ultimate goal
to knock down Fgfr4 in mice lacking Fgfr1 and Fgfr2 in hepato-
cytes (Alb-R1/R2 mice10), Alb-Cre mice were used for all
follow-up studies since they are the appropriate control for
Alb-R1/R2 mice.
Efﬁcient knockdown of Fgfr4 was veriﬁed by qRT-PCR using
RNAs from total liver or cultured primary hepatocytes and by
western blotting using total liver lysates (ﬁgure 1B). The similar
knockdown efﬁciency seen with lysates from total liver and
from isolated hepatocytes is consistent with the strong expres-
sion of Fgfr4 by hepatocytes, but not by non-parenchymal cells
(see online supplementary ﬁgure S1B). Efﬁcient knockdown by
Fgfr4 siRNA was conﬁrmed for all time points and by Fgfr4-2
siRNA for the 48 h time point, while expression of other Fgfr
was not affected (see online supplementary ﬁgure S1C–E).
Knockdown of Fgfr4 did not cause liver injury within the ana-
lysed time frame as revealed by normal serum levels of aspartate
and alanine aminotransferases (AST and ALT) (ﬁgure 1C) and
the normal liver histology (see online supplementary ﬁgure
S1F). Most control mice survived the ﬁrst week after PH,
whereas 25% of the mice with Fgfr4 knockdown died between
48 and 216 h after surgery (see online supplementary ﬁgure
S2A). ALTand AST levels were increased compared with control
mice at 24 and 48 h after PH (ﬁgure 1C). Severe necrosis was
observed up to 48 h, in particular around portal areas (ﬁgure
1D), and there was enhanced steatosis, neutrophil inﬁltration
and an increase in the number of apoptotic cells (see online sup-
plementary ﬁgure S2B–D). Their small nuclei suggest that the
apoptotic cells are predominantly non-parenchymal cells. The
damage was, however, repaired during the following days
(ﬁgure 1D). The peak in hepatocyte DNA replication that
occurred in control mice at 48 h after PH was not observed
after Fgfr4 knockdown. There was no compensatory hyperproli-
feration at later time points (ﬁgure 1E) and also no increase
compared with control at 36 h (data not shown). Since we still
observed a strong knockdown after 9 days (see online supple-
mentary ﬁgure S1C), it is unlikely that cells with inefﬁcient
knockdown preferentially contributed to regeneration.
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Similar regeneration defects were observed with Fgfr4-2
siRNA (ﬁgure 1D, E), and the more efﬁcient siRNA (Fgfr4) (see
online supplementary ﬁgure S1A) caused a stronger phenotype
compared with the less efﬁcient siRNA (Fgfr4-2). Mice injected
with Luc siRNA did not exhibit necrosis (ﬁgure 1D), and the
time course of regeneration as well as AST/ALT levels after PH
Figure 1 Impaired liver regeneration in mice after knockdown of Fgfr4 in hepatocytes. (A) Schematic representation of the experimental setup.
Mice were injected twice with Fgfr4 or Luc siRNA with a time interval of 5 days. After additional 5 days, they were subjected to two-third (partial)
hepatectomy (PH). (B) Knockdown of Fgfr4 was veriﬁed by qRT-PCR using RNA from total liver or cultured primary hepatocytes. N=3–7 per
treatment group. Expression levels in mice treated with Luc siRNA were arbitrarily set as 1. (C) Activities of ALT and AST in the serum were
determined in non-injured mice (n.i.) and at different time points after PH (N=3–9). (D) Morphometric analysis of the necrotic damage using
H&E-stained liver sections at different time points after PH in mice injected with Fgfr4 siRNA and at 48 h in mice injected with Fgfr4-2 siRNA.
N=4–9. Representative sections from mice 48 h after PH are shown below. Necrotic areas are encircled with dotted lines. Scale bar: 100 μM.
(E) BrdU-positive cells were counted in liver sections at different time points after PH in mice injected with Fgfr4 siRNA and at 48 h in mice injected
with Fgfr4-2 siRNA. N=4–9. Representative sections stained with a BrdU antibody are shown for the 48 h time point. Scale bar: 50 μM. (F) Levels of
Fgf15 in the serum were determined in non-injected mice and at different time points after PH. N=3–5. All bars represent mean ±SEM. ALT, alanine
transaminase; AST, aspartate transaminase; BrdU, 5-bromo-20-deoxyuridine; Fgfr, ﬁbroblast growth factor receptor; Luc, luciferase.
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were similar as in mice not injected with any siRNA18 (and data
not shown). This ﬁnding demonstrates lack of toxicity of the
nanoparticles even after liver injury.
Levels of the major Fgfr4 ligand, Fgf15,21 strongly increased
in the serum of control mice within 6–24 h after PH, most
likely as a result of release of intrahepatic bile acids into the
intestine after surgery. This increase was much more pro-
nounced after Fgfr4 knockdown (ﬁgure 1F), possibly due to
higher levels of bile acids that stimulate Fgf15 expression in the
intestine,21 since activation of Fgfr4 by intestinal Fgf15 sup-
presses bile acid production.11 Indeed, expression of cholesterol
7 α-hydroxylase (Cyp7a1), the rate-limiting enzyme in bile acid
production,22 was increased in mice with Fgfr4 knockdown
prior to PH (see online supplementary ﬁgure S3A), and the con-
centrations of intrahepatic bile acids, in particular of tauro-
conjugated bile acids, were signiﬁcantly higher than in control
mice at 24 and 48 h after PH (table 1 and see online supple-
mentary ﬁgure S3B). The increase in bile acids in the liver
during regeneration provides an explanation for the liver necro-
sis since bile acids can damage cell membranes due to their
detergent properties.23 The necrosis is most likely not due to
increased fragility of bile ductules in the absence of Fgfr4 since
staining with a pan-keratin antibody revealed no obvious defect
in the integrity of bile ducts at periportal locations (see online
supplementary ﬁgure S3C).
Loss of Fgfr4 induces compensatory hepatocyte growth
In spite of the defect in DNA replication by hepatocytes, the
liver to body weight ratio was only mildly reduced in the Fgfr4
knockdown mice 96 and 216 h after PH (ﬁgure 2A), suggesting
that cellular hypertrophy compensates at least in part for the
proliferation defect. Indeed, hepatocytes of these mice were
signiﬁcantly larger at 216 h after PH compared with control
mice, and more cells were binuclear at this time point (ﬁgure
2B, C). There was also a strong reduction in mitotic ﬁgures 48 h
after PH. However, this was followed by an increase at 72 h
(ﬁgure 2D), demonstrating that cell division eventually
occurred, although with a severe delay.
Fgfr4 signalling is important for Stat3 activation and
PH-induced expression of the forkhead box protein M1
(Foxm1)
Consistent with the defect in cell cycle progression upon Fgfr4
knockdown, expression of cyclins A2 and B1 was reduced at
48 h after PH compared with Luc siRNA injected mice, while
cyclins D1 and E1 were only moderately affected (ﬁgure 3A–D).
Upregulation of Foxm1, a transcription factor with a crucial role
in hepatocyte DNA replication and mitosis after PH,24 occurred
48 h after PH in control mice, but to a much lesser extent in
Fgfr4 knockdown mice (ﬁgure 3E). This was not due to altera-
tions in the expression of the farnesoid X receptor (Fxr), a
direct activator of the Foxm1 gene (ﬁgure 3F). However, levels
of phosphorylated (activated) Stat3, a positive regulator of the
Foxm1 gene,25 were much lower in Fgfr4 knockdown mice at
24 h after PH compared with controls, while the early Stat3
activation was not affected (ﬁgure 3G). This was not a conse-
quence of interleukin (IL)-6 deﬁciency since serum levels of
IL-6 and its upstream regulator tumour necrosis factor-α were
even increased in mice with Fgfr4 knockdown at this time point
(see online supplementary ﬁgure S4A,B). Rather, it seems to be
a direct consequence of the reduction in Fgfr4 levels since Fgfr4
knockdown in mouse hepatoma cells also reduced Stat3 phos-
phorylation. Concomitantly, DNA synthesis was reduced and
cells in G1 accumulated, whereas those in S or G2 phase were
Table 1 Enhanced levels of bile acids in mice with Fgfr4 knockdown
Bile acid SPECIES
n.i. 24 h 48 h 72 h
Luc Fgfr4 Luc Fgfr4 Luc Fgfr4 Luc Fgfr4
Total 243.5±58.9 194±33.8 538.2±427.9 2486.2±1424.1 183.3±36.3 1508.1±656* 331.8±84.1 430.4±171.2
Free 0.1±0.1 0±0 1±1 33.5±24.6 0±0 3.8±2.4 0±0 1.4±1.3
Primary 215.4±54.4 172.9±32.9 524.6±428 2432±1389.9 168.3±34.4 1493.9±658.9 321.3±84 420.6±171.7
Secondary 28.1±4.6 21.1±5.9 13.6±2.3 54.2±36 15.1±3.3 14.2±3 10.4±3.3 9.8±0.8
Tauro 243.3±58.9 194±33.8 537.2±426.9 2452.7±1399.7 183.3±36.3 1504.3±653.7* 331.7±84.1 429±170.3
FREE
Primary
CA 0.1±0.1 0±0 1±1 32.3±23.6 0±0 3.8±2.4 0±0 1.4±1.3
Secondary
HDCA 0±0 0±0 0±0 0.9±0.7 0±0 0±0 0±0 0±0
DCA 0±0 0±0 0±0 0.2±0.2 0±0 0±0 0±0 0±0
LCA 0±0 0±0 0±0 0±0 0±0 0±0 0±0 0±0
TAURO-CONJUGATED
Primary
TCA 203.4±53 166.8±31.6 517.4±425.2 2393.1±1363.8 158.3±34.1 1474.4±657.9* 303.3±82.8 399.6±172.1
TCDCA 11.8±2.5 6.1±1.3 6.2±1.7 6.6±2.8 9.9±0.8 15.7±1.4* 18±5.5 19.5±2.1
Secondary
TUDCA 18.5±2.3 10.5±4.2 5.3±1.3 24±18.4 6.5±1.4 7.2±1.4 4.1±1.5 7.3±1.6
THDCA 3±1.3 3±0.7 3.7±0.8 12.7±9.5 4.9±1.6 4.2±0.7 3.8±1.3 0.8±0.3
TDCA 6.6±1.7 7.6±1.4 4.6±2.9 16.3±7.6 3.7±1 3.5±1 2.5±1.3 2.5±0.7
Levels of individual intrahepatic bile acids were determined prior to and at different time points after PH using liquid chromatography—mass spectrometry and are shown as nanomole
bile acid per gram liver tissue. Values indicate mean±SEM. Bile acids, which were significantly higher in mice with Fgfr4 knockdown compared with mice injected with Luc siRNA are
indicated with *.
CA, cholic acid; DCA, deoxycholic acid; Fgfr, fibroblast growth factor receptor; HDCA, hyodeoxycholic acid; LCA, lithocholic acid; Luc, luciferase; n.i., non-injured mice; PH, partial
hepatectomy; TCA, taurocholic acid; TCDCA, taurochenodeoxycholic acid; TDCA, taurodeoxycholic acid; THDCA, taurohyodeoxycholic; TUDCA, tauroursodeoxycholic acid.
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reduced (see online supplementary ﬁgure S5A–C). Furthermore,
levels of Foxm1 and cyclin A2 and B1 mRNAs were strongly
reduced in Hepa1-6 and AML12 cells upon transfection with
Fgfr4 and Fgfr4_2 siRNAs (see online supplementary ﬁgure S5D
and data not shown).
Fgfr signalling is essential for liver regeneration
Finally, we determined whether Fgfr1 and Fgfr2 prevent a more
severe phenotype in Fgfr4 knockdown mice. For this purpose,
we injected Luc or Fgfr4 siRNA into Alb-R1/R2 mice or
Alb-Cre mice. Alb-R1/R2 mice showed impaired expression of
genes required for compound detoxiﬁcation, resulting in liver
necrosis and an almost 50% reduction in survival upon PH
when ketamine/xylazine was used for anaesthesia.10 Since the
extent of liver injury and the resulting mortality were much
lower with isoﬂurane anaesthesia,10 we used these conditions
for our experiments. While Alb-R1/R2 mice with Fgfr4 knock-
down (Alb-R1/R2-Fgfr4 mice) survived the ﬁrst two days after
PH, they subsequently showed signs of liver failure and they
died or had to be sacriﬁced due to health problems (ﬁgure 4A).
BrdU staining and expression analysis of cyclins A2 and B1
revealed strongly reduced hepatocyte proliferation in the
remaining mice at 72 h, and at this time we also observed
massive necrosis, liver damage and steatosis (ﬁgure 4B–E). In
addition, Fgf15 serum levels were dramatically increased (ﬁgure
4E), indicating high levels of bile acids that reach the intestine.
Indeed, levels of intrahepatic bile acids were already higher
prior to PH in Alb-R1/R2-Fgfr4 mice and dramatically increased
at 72 h after PH when liver failure occurred (ﬁgure 4E and see
online supplementary table S1). Thus, in contrast to mice deﬁ-
cient in only Fgfr4, levels of intrahepatic bile acids did not
decrease after 48 h in Alb-R1/R2-Fgfr4 mice, and the animals
were not able to repair the necrotic damage. These results dem-
onstrate that Fgfr signalling in hepatocytes is essential for liver
regeneration.
DISCUSSION
We demonstrate a severe impairment of liver regeneration upon
knockdown of Fgfr4 in hepatocytes, consistent with the import-
ant role of Fgfr4 in liver tumorigenesis through its effect on
hepatoma cell proliferation and survival.12 Thus, targeting this
receptor is a potential treatment option for this malignancy.13 26
Surprisingly, however, mice with a global Fgfr4 knockout exhib-
ited no defect in hepatocyte proliferation after PH, and recovery
of their liver mass was not affected.11 The different results
obtained with Fgfr4 knockout versus knockdown mice may
result from activation of compensatory mechanisms in the
knockout mice during prenatal or postnatal development. They
Figure 2 Compensatory growth of hepatocytes after PH in mice with Fgfr4 knockdown. (A) Liver to body weight ratio in non-injured mice and at
different time points after PH in mice injected with Fgfr4 or Luc siRNA. N=3–9 mice per treatment group. (B) Size of hepatocytes as determined on
sections stained with rhodamine-coupled phalloidin. (C) The percentage of binucleated cells was determined on sections stained with
rhodamine-coupled phalloidin. (D) Cells with mitotic ﬁgures (indicated by arrows in the representative stainings) were quantiﬁed in H&E-stained
sections. Approximately 50 cells from three to seven mice were counted in (B–D). Magniﬁcation bar: 50 μm. Bars represent mean±SEM. Fgfr,
ﬁbroblast growth factor receptor; Luc, luciferase; PH, partial hepatectomy.
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are unlikely caused by off-target effects of the siRNA since the
same abnormalities were observed with two different Fgfr4
siRNAs. In addition, toxicity of the nanoparticles was excluded
since we did not observe liver abnormalities in mice after injec-
tion of nanoparticles with Luc siRNA—not even after PH. Most
importantly, loss of Fgf15 caused similar alterations in liver
regeneration as seen after Fgfr4 knockdown,27 28 and loss of
Fxr in the intestine also resulted in impaired hepatocyte prolif-
eration after PH, which was rescued by adenoviral overexpres-
sion of Fgf15.29 However, the strong lethality observed after
PH in Fgf15 knockout mice27 was not observed in Fgfr4 knock-
down animals and we also did not ﬁnd a reduction in Fxr or
cyclin D1 expression after Fgfr4 knockdown. Fgf15 can also
activate the IIIc variants of Fgfr1, Fgfr2 or Fgfr3,30 which are
expressed on non-parenchymal cells, and this may contribute to
the effect of Fgf15 on liver regeneration. Hepatocytes only
express the IIIb variants of Fgfr1 and Fgfr2,10 which are most
likely not activated by Fgf15. However, we cannot fully exclude
the possibility that Fgf15 activates these receptors in hepatocytes
in vivo. Finally, activation of Fgfr4 by Fgf15 in other organs,
which are not targeted by the siRNA, may contribute to the
effect of Fgf15 on liver regeneration. However, it seems most
likely that very low levels of Fgfr4 that remain in the liver of
the siRNA-treated mice are sufﬁcient to maintain normal
Figure 3 Cell cycle progression is impaired in mice with Fgfr4 knockdown. (A–F) qRT-PCR analysis of different cyclins and of Foxm1 and Fxr using
RNAs from liver at different time points after PH. N=3–9 per time point and treatment group. Expression levels in non-injured liver of mice injected
with Luc siRNA were arbitrarily set as 1. (E and G) Total liver lysates of mice prior to and at different time points after PH were analysed by western
blotting for expression of Foxm1 and Gapdh (E), or total and phosphorylated Stat3 (G). The ratio between phosphorylated and total Stat3 is shown.
All bars represent mean±SEM. Fgfr, ﬁbroblast growth factor receptor; Luc, luciferase; PH, partial hepatectomy.
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expression levels of cyclin D1 and Fxr and to allow survival.
Alternatively, differences in the analgesia or anaesthesia, the sur-
gical procedure and/or the genetic background may contribute
to the differences in liver regeneration between Fgfr4 knock-
down and Fgf15 knockout mice.
Our mechanistic studies combined with published data
strongly suggest that an Fgf15-Fgfr4-Stat3-Foxm1 axis controls
hepatocyte DNA replication and proliferation in the regenerat-
ing liver. This hypothesis is based on the following ﬁndings: (i)
Fgf15 serum levels strongly increased after PH, (ii) loss of Fgf15
caused a similar regeneration defect as knockdown of Fgfr4, (iii)
activation of Stat3 and induction of Foxm1 expression by PH
were strongly reduced upon knockdown of Fgfr4 in the liver
and (iv) knockdown of Fgfr4 in cultured hepatoma cells also
Figure 4 Fgfr signalling is essential for liver regeneration. Alb-R1/R2 mice or Alb-Cre control mice were injected with Fgfr4 or Luc siRNA and
subjected to PH. Survival of mice of all genotypes and treatment groups is shown on (A). The number on top of the bars indicates the number of
mice included in the analysis at each time point. (B) Left panel: BrdU-positive cells were counted in liver sections 72 h after PH in Alb-R1/R2 mice
and Alb-Cre control mice injected with Fgfr4 or Luc siRNA. N=4–9 per time point and treatment group. Right panels: qRT-PCR analysis of cyclins A2
and B1 using RNAs from liver at 0 h and 72 h after PH. N=3–9 per time point and treatment group. Expression levels in mice injected with Luc
siRNA 0 h after PH were arbitrarily set as 1. N=4–9. (C) The necrotic area (encircled with dotted line) was determined in H/E-stained sections. N=4–
9. (D) AST and ALT activities in the serum of mice of all treatment groups at 72 h after PH. N=4–9. (E) Hepatic steatosis as determined by Oil Red O
staining of liver sections. Representative sections from 3–10 mice per treatment group are shown. (F) Serum levels of Fgf15 at different time points
after PH. N=3–5. (G) Levels of total intrahepatic bile acids were determined using liquid chromatography—mass spectrometry. N=3–5. All bars
represent mean±SEM. ALT, alanine transaminase; AST, aspartate transaminase; BrdU, 5-bromo-20-deoxyuridine; Fgfr, ﬁbroblast growth factor
receptor; Luc, luciferase; PH, partial hepatectomy.
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reduced the levels of pStat3 and concomitantly resulted in accu-
mulation of cells in G1 and in reduction of DNA synthesis. We
propose that the failure to induce Foxm1 expression after PH is
primarily responsible for the impaired DNA replication in hepa-
tocytes since Foxm1-deﬁcient mice showed similar abnormalities
and also lacked the strong peak of hepatocyte DNA replication
that is normally seen 36–48 h post PH.24 By contrast, these
mice did not show liver necrosis, indicating that the necrosis
seen after PH in Fgfr4 knockdown mice is Foxm1 independent.
In addition, it is obviously not due to major damage of the
portal bile ductules. Rather, it seems most likely that the effect
of Fgfr4 on bile acid metabolism11 31 underlies this phenotype.
Similar as in Fgf15-deﬁcient mice, this leads to accumulation of
cytotoxic bile acids in the liver after PH. The enhanced expres-
sion of Cyp7a1 in the non-injured liver of control mice com-
pared with Fgfr4 knockdown mice provides a partial
explanation for this ﬁnding. However, the PH-induced down-
regulation of Cyp7a1 expression32 was not affected in Fgfr4
knockdown mice. This down-regulation was shown to depend
on Hgf,33 which was normally expressed in Fgfr4 knockdown
mice (see online supplementary ﬁgure S6A). Therefore, add-
itional mechanisms, such as defects in the PH-induced regula-
tion of different transporters,23 32 are likely to contribute to the
accumulation of bile acids in the liver, which remain to be deter-
mined. Consistent with the increase in bile acids, which stimu-
late expression of Fgf15 in the intestine via activation of Fxr,21
serum levels of Fgf15 were much higher in Fgfr4 knockdown
mice compared with Luc siRNA-injected mice after PH.
The most dramatic result of our study was the liver failure
that occurred between 48 and 72 h after PH in Alb-R1/
R2-Fgfr4 mice. This resulted from severe liver necrosis, which
—in contrast to mice with loss of only Fgfr4 or Fgfr1/Fgfr2—
could not be repaired. The necrosis is most likely the conse-
quence of the prolonged increase in intrahepatic bile acids after
PH, which causes continuous cell damage. The molecular
mechanisms underlying this strong increase are as yet unknown
since Cyp7a1 expression was not signiﬁcantly altered in Alb-R1/
R2-Fgfr4 mice prior and following PH (see online supplemen-
tary ﬁgure S6B), possibly due to activation of compensatory
mechanisms. Therefore, Fgfr deﬁciency seems to affect other
steps in bile acid metabolism and/or transport, which should be
addressed in future studies. The bile acid toxicity in combin-
ation with the repair defect ultimately resulted in liver failure.
The severe lipid accumulation that we observed after PH is
likely to further contribute to the severe regeneration phenotype
since hepatic steatosis has been shown to affect hepatocyte pro-
liferation after PH.34 35
Taken together, our results revealed that Fgfs and their recep-
tors are essential orchestrators of liver regeneration. This is
likely to be of major medical relevance because the remarkable
capacity of the liver to regenerate is insufﬁcient after chronic
injury or upon removal of particularly large amounts of liver
tissue. In the latter case, the remaining liver tissue is too small
to fulﬁl the important functions of this organ in metabolism
and detoxiﬁcation, ultimately resulting in small-for-size syn-
drome and liver failure. Remarkably, the reduced survival that
occurs after extended PH (86%) was partially rescued by adeno-
viral delivery of Fgf15.27 Furthermore, inducible overexpression
of Fgf7 in transgenic mice prevented chronic liver damage and
even stimulated repair after chronic injury, most likely through
the activation of Fgfr2-IIIb on liver progenitor cells.36 Thus,
Fgfs are emerging as promising therapeutics for the prevention
and/or treatment of liver damage and for the improvement of
the regeneration process in this organ.
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